Live
- A Guide to Temperature and Humidity Standards in Data Center Server Rooms
- Gadwal collector briefs on details of voters
- Jupally Krishna Rao takes part in Alampur rallu
- Bharath Prasad files 3rd Nomination
- Baisakh Month: A Time of Auspicious Beginnings and Sacred Festivals
- Oust BJD govt for overall development, says Shah
- Unveiling the Hidden Gems: Surprising Health Benefits of Garlic Peels
- Overcoming Sleep Struggles: A Comprehensive Guide to a Restful Night
- RTC bus hit the auto
- MLA Kuchukula Rajesh Reddy participated in the Birappa festival
Dr Reddy’s out licenses steroid DFD-06 to Encore
Highlights
Drug major Dr Reddy’s Laboratories (DRL) has out-licensed the future development, manufacturing and commercialisation rights of its topical high potency steroid DFD-06 to Encore Dermatology. The drug is used for treatment of moderate to severe plaque psoriasis.
Hyderabad: Drug major Dr Reddy’s Laboratories (DRL) has out-licensed the future development, manufacturing and commercialisation rights of its topical high potency steroid DFD-06 to Encore Dermatology. The drug is used for treatment of moderate to severe plaque psoriasis.
Dr Reddy’s Laboratories in a communique to BSE said: “Under the terms of agreement, Encore will be responsible for the commercialisation of DFD-05 in the United States.” Promius Pharma, a wholly-owned subsidiary of Dr Reddy’s, is eligible to receive certain pre and post commercialisation milestone payments of up to $32.5 million, followed by fixed royalty.
Next Story
ADVERTISEMENT
